Scientific paper - Original scientific paper
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes & Endocrinology, 7 (2019), 8; 618-628. https://doi.org/10.1016/s2213-8587(19)30158-5

Ray, Kausik K.; Colhoun, Helen M.; Szarek, Michael; Baccara-Dinet, Marie; Bhatt, Deepak L.; Bittner, Vera A.; Budaj, Andrzej J.; Diaz, Rafael; Goodman, Shaun G et all.; Reiner, Željko; Peršić, Viktor

Cite this document

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara Dinet, M., Bhatt, D. L., Bittner, V. A. ... Peršić, V. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology, 7. (8), 618-628. doi: 10.1016/s2213-8587(19)30158-5

Ray, Kausik K., et al. "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial." The Lancet Diabetes & Endocrinology, vol. 7, no. 8, 2019, pp. 618-628. https://doi.org/10.1016/s2213-8587(19)30158-5

Ray, Kausik K., Helen M. Colhoun, Michael Szarek, Marie Baccara Dinet, Deepak L. Bhatt, Vera A. Bittner, Andrzej J. Budaj, et al. "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial." The Lancet Diabetes & Endocrinology 7, no. 8 (2019): 618-628. https://doi.org/10.1016/s2213-8587(19)30158-5

Ray, K. K., et al. (2019) 'Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial', The Lancet Diabetes & Endocrinology, 7(8), pp. 618-628. doi: 10.1016/s2213-8587(19)30158-5

Ray KK, Colhoun HM, Szarek M, Baccara Dinet M, Bhatt DL, Bittner VA, and sur.. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology [Internet]. 2019 [cited 2024 May 30];7(8):618-628. doi: 10.1016/s2213-8587(19)30158-5

K. K. Ray, et al., "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial", The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:784502. [Accessed: 30 May 2024]